Merck & Co., Inc. $MRK Shares Sold by Tectonic Advisors LLC

Tectonic Advisors LLC decreased its holdings in Merck & Co., Inc. (NYSE:MRK) by 4.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 121,391 shares of the company’s stock after selling 5,293 shares during the quarter. Merck & Co., Inc. makes up 0.8% of Tectonic Advisors LLC’s investment portfolio, making the stock its 27th biggest holding. Tectonic Advisors LLC’s holdings in Merck & Co., Inc. were worth $17,639,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Winthrop Advisory Group LLC grew its position in Merck & Co., Inc. by 8.6% in the 3rd quarter. Winthrop Advisory Group LLC now owns 8,617 shares of the company’s stock worth $1,259,000 after purchasing an additional 686 shares in the last quarter. Barrett & Company Inc. boosted its stake in Merck & Co., Inc. by 11.7% in the third quarter. Barrett & Company Inc. now owns 6,042 shares of the company’s stock valued at $878,000 after acquiring an additional 631 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its stake in shares of Merck & Co., Inc. by 7.4% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 78,616 shares of the company’s stock worth $11,424,000 after purchasing an additional 5,418 shares during the last quarter. BRIA Capital Group LLC increased its position in Merck & Co., Inc. by 22.8% in the third quarter. BRIA Capital Group LLC now owns 5,973 shares of the company’s stock worth $868,000 after buying an additional 1,110 shares during the last quarter. Finally, Rede Wealth LLC purchased a new position in shares of Merck & Co., Inc. during the 3rd quarter valued at $204,000. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported positive Phase 3 INTerpath-001 results for the personalized melanoma vaccine, intismeran, combined with Keytruda. The treatment reduced the risk of recurrence or death by 42% and also improved distant metastasis-free survival, supporting the long-term potential of the partnership’s oncology pipeline. Doctors call Moderna and Merck cancer vaccine data a major advancement
• Positive Sentiment: The European Commission approved Keytruda plus Padcev as a perioperative treatment for resectable muscle-invasive bladder cancer, regardless of patients’ cisplatin eligibility. The broader label expands the addressable market and represents the EU’s first approval of a PD-1 inhibitor combined with an antibody-drug conjugate in this setting. Merck wins EU approval for Keytruda plus Padcev
• Neutral Sentiment: Despite strong clinical results, the vaccine announcement triggered a “sell-the-news” reaction. The data largely met elevated Wall Street expectations after an earlier leak, limiting the immediate upside for MRK even though oncologists viewed the results as an important treatment advance. Merck and Moderna shares fall on cancer vaccine results
• Negative Sentiment: Investors remain concerned about valuation and Merck’s future revenue concentration in Keytruda ahead of its patent cliff. Analysts have also characterized the recent rally as leaving limited margin of safety, increasing the risk of profit-taking when news is merely in line with expectations. Merck rally leaves little margin of safety
• Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate to $2.63 from $2.73 and its FY2027 estimate to $9.38 from $9.47. Separate previews also anticipate a year-over-year decline in quarterly earnings, adding near-term pressure to the shares. Merck earnings preview

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on MRK shares. Weiss Ratings upgraded Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 25th. Morgan Stanley cut their price objective on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research report on Wednesday, October 7th. Barclays increased their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Wolfe Research raised their price target on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a report on Tuesday, August 25th. Finally, UBS Group upped their price target on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Seventeen analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $151.92.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Richard R. Deluca sold 11,699 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the sale, the executive vice president directly owned 110,167 shares in the company, valued at $14,501,282.21. This trade represents a 9.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by insiders.

Merck & Co., Inc. Trading Down 1.4%

NYSE:MRK traded down $1.99 during midday trading on Friday, reaching $145.25. 8,379,092 shares of the stock traded hands, compared to its average volume of 9,663,986. The stock has a market capitalization of $358.35 billion, a P/E ratio of 116.20, a PEG ratio of 6.83 and a beta of 0.21. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The company has a fifty day moving average of $146.98 and a 200 day moving average of $130.17. Merck & Co., Inc. has a 12 month low of $82.01 and a 12 month high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts predict that Merck & Co., Inc. will post 2.64 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were issued a $0.85 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.’s payout ratio is 272.00%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.